Page 3 - Brianm Strem News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Kiora Pharmaceuticals (KPRX) Receives $1 2M in Research Tax Credits

Kiora Pharmaceuticals (KPRX) Receives $1 2M in Research Tax Credits
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New south walesBrianm stremKiora pharmaceuticals incKiora pharmaceuticalsRetinitis pigmentosa

Kiora s Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind

Kiora s Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New south walesSouth australiaFrancina agostiBrianm stremRobert cassonEric danielsKiora pharmaceuticalsAssociation for researchNational eye instituteCalifornia newsfile corpPrincipal investigatorRoyal adelaideChief development officerPhotoswitch moleculeRetinitis pigmentosaOcular presentation

Kiora Pharmaceuticals, Inc : Kiora s Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind

Encinitas, California (Newsfile Corp. - April 27, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) presented preliminary results from an ongoing clinical trial showing its investigational drug, KIO-301,

New south walesSouth australiaEric danielsFrancina agostiRobert cassonBrianm stremNational eye instituteAssociation for researchCalifornia newsfile corpKiora pharmaceuticalsPrincipal investigatorRoyal adelaideChief development officerPhotoswitch moleculeRetinitis pigmentosaOcular presentation

Kiora Pharmaceuticals, Inc : Kiora Pharmaceuticals KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects

In a second presentation, Kiora shared additional positive results for its KIO-100 platform in the treatment of autoimmune uveitis. Encinitas, California (Newsfile Corp. - April 26, 2023) - Kiora Pharmaceuticals

Brianm stremFrancina agostiEnriqueo graue hernandezCalifornia newsfile corpKiora pharmaceuticalsAssociation for researchPersistent corneal epithelial defectsChemically modified formHyaluronic acidImproves wound healingPersistent corneal epithelial defectPrincipal investigatorOcular presentationRheumatoid arthritisDihydroorotate dehydrogenasePrivate securities litigation reform act

Kiora Pharmaceuticals (KPRX) KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects

Kiora Pharmaceuticals (KPRX) KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Enriqueo graue hernandezBrianm stremAssociation for researchKiora pharmaceuticalsWall streetPersistent corneal epithelial defectsChemically modified formHyaluronic acidImproves wound healingPersistent corneal epithelial defectPrincipal investigator